Tizona Therapeutics, Inc., is an immunology company harnessing the power of the immune system to develop treatments for cancer.

Our Approach

Tizona develops next-generation immunotherapies

The successful development of immunotherapies represents one of the most important and exciting breakthroughs in cancer. Recent approvals of checkpoint inhibitors provide evidence that the immune system is capable of recognizing cancerous cells and eradicating them. These checkpoint inhibitors can achieve complete, durable remissions and help patients live longer. Yet, despite this progress, existing immunotherapies are effective in a relatively small number of patients and types of cancer.

Tizona’s therapies are designed to modulate the activity of immunosuppressive cells by targeting the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment:

  • Immune suppressive cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tolerogenic dendritic cells (DCs)
  • Inhibitory / suppressive cytokines and metabolic pathways

Our distinct approach to Tumor Immunotherapy

Conventional Immunotherapy Approaches
T cell Priming, Activation & Proliferation
  • Checkpoint inhibitors (e.g., CTLA4, PD-1)
  • Coactivators (e.g., 4-1BB)
  • Vaccines (peptide, DNA, DC, artificial APCs, etc.)
  • Oncolytic Viruses
  • Cytokines (IL-12, IL-15, IL-21)
Current Approach
Immunosuppressive Tumor Microenvironment
  • Tregs
  • TAMs, MDSCs, tolerogenic DCs
  • Inhibitory cytokines
Area of Interest
T cell Trafficking & Infiltration
  • Chemokines
  • Immuno-repellent factors

Our Team

Tizona’s expert team of scientific advisors, board of directors and accomplished team position the company to become a leader in next generation immuno-oncology development.

Pablo J. Cagnoni, M.D.
President & Chief Executive Officer
Pablo is President and CEO of Tizona. Over of the course of his career as an oncologist and pharmaceutical...  Full Bio

Jeremy Bender, Ph.D., M.B.A.
Chief Operating Officer
Jeremy joined Tizona as COO in July of 2015. In his role, he oversees the company’s finance, operations, alliance,...  Full Bio

Courtney Beers, Ph.D.
Vice President, Immunology
Courtney is the Vice President of Cancer Immunotherapy for Tizona. She is leading discovery and development work on Tizona’s...  Full Bio

John Corbin, Ph.D.
Vice President, Antibody Development
John joined Tizona as Vice President of Antibody Development in 2016. In his role, he is responsible for antibody...  Full Bio

Svetlana Lucas, Ph.D.
Vice President, Business Development
Svetlana joined Tizona Therapeutics as Vice President of Business Development in July of 2015. In her role, she is...  Full Bio

Christine O'Brien
Vice President of Program Management
Christine O’Brien is Vice President of Program Management for Tizona Therapeutics, where she is responsible for ensuring the successful...  Full Bio

Board of Directors